ActivHeal® Cuts Costs

Dec 9, 2009

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 8082D
Advanced Medical Solutions Grp PLC
09 December 2009
 



For immediate release

December 2009

                    

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Major London Teaching Hospital endorses financial savings offered by ActivHeal® range

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that its ActivHeal® value range of advanced woundcare dressings has delivered annualised cost savings of 54% to University College London Hospitals NHS Foundation Trust (UCLH) whilst maintaining a high standard of clinical care.

These findings were reported in an article entitled “Using ActivHeal® dressings in a London teaching hospital: a cost analysis” published in a recent edition of the British Journal of Nursing 2009 (Tissue Viability Supplement) Vol 18 No 20, by Sarah Lewis, Tissue Viability Nurse UCLH.

ActivHeal® is a value range of products provided directly to the NHS by AMS as a first line therapy for routine wounds. These complement the use of AMS’s new technologies, such as silver alginatewhich are sold through strategic partners for treating more difficult wounds.

The ActivHeal® range offers equivalent technical and clinical performance to similar branded products but at a substantially reduced cost thereby delivering real and immediate savings to the NHS. This potential saving is estimated to be of the order of £25 million per year in the UK which helps to balance budgets and afford new technologies for problematic cases.    ActivHeal® products are currently used in around half of the NHS Foundation and Acute Hospital Trusts in the UK. Hospital usage represents around 25% of the current £100 million NHS spend on advanced woundcare dressings with the majority being in the community.

In the study reported in the British Journal of Nursing, the ActivHeal® range of dressings consisting of foams, films, alginates, gels and hydrocolloids were substituted for “branded” dressings over a three-month period in 2007 during which time dressing cost and clinical effectiveness were assessed. The result was an equivalent yearly cost saving of £55,221 (54%) with retention of performance standards across the dressing range. 

The study adds: “Two years after the trial, wards in University College London Hospitals NHS Foundation Trust continue to benefit from significant annual cost savings on dressings by using the ActivHeal® range of products, while maintaining a high standard of clinical care.

Commenting on this announcement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions, stated:

This study, which fully endorsed the ActivHeal® value offering, is of particular relevance because pressure on healthcare budgets is putting increasing importance on the achievement of cost savings without compromising patient care.

This “in-use” study at a major London teaching hospital rated the dressings as “equivalent to” or “better than” the original dressings in almost all cases and allowed a significant cost saving to be made by switching to ActivHeal®.”


For further information, please contact:

Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer

Mary Tavener, Finance Director

www.admedsol.com

  Tel: +44 (0) 1606 545508

Buchanan Communications

Mark Court / Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Notes to Editors:

Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NRAUWAWRKRRURAA

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.